In vitro data suggest that chemotherapy combined with an EGFR-TKI may act in concert in EGFR-mutated NSCLC.27 The FLAURA2 trial indicated that the combination of osimertinib and chemotherapy improved PFS over osimertinib alone as first-line treatment for EGFR-mutated advanced NSCLC.28 Sequential use of chemotherapy and an EGFR-TKI as adjuvant treatment to eliminate minimal residual disease may be a rational option for resected EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.